SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

Stefan Schreiber  1     Geert R. D'Haens  2     Fraser Cummings  3     Peter Irving  4     Byong Duk Ye  5     Yoorim An  6     Dong-Hyeon Kim  6     Sangwook Yoon  6     Shomron Ben-Horin  7     Walter Reinisch  8    
1 University Hospital Schleswig-Holstein, Kiel, Germany
2 Amsterdam University Medical Centers, Amsterdam, Netherlands
3 University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
4 Guy’s and St Thomas’ Hospital, London, United Kingdom
5 University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of
6 Celltrion Healthcare, Incheon, Korea, Republic of
7 Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
8 Medical University of Vienna, Vienna, Austria

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing